Micro Cap
Diagnostics & Research
Stocks Ranked by
Market Capitalization
| Name | Market cap | Price |
Price change % |
|
|---|---|---|---|---|
1
Biodesix
BDSX
$250M
| $250M | $23.66 | 4.25% |
|
2
Exagen
XGN
$187M
| $187M | $7.72 | 9.81% |
|
3
Burning Rock Biotech
BNR
$136M
| $136M | $12.90 | 17.3% |
|
4
Insight Molecular Diagnostics
IMDX
$98.5M
| $98.5M | $3.01 | 1.63% |
|
5
Quantum Cyber N.V.
QUCY
$89.1M
| $89.1M | $1.06 | 2.75% |
|
6
Precipio
PRPO
$38.3M
| $38.3M | $21.38 | 5.15% |
|
7
MDxHealth
MDXH
$19.7M
| $19.7M | $0.2066 | 65.8% |
|
8
American Shared Hospital Services
AMS
$8.51M
| $8.51M | $1.28 | 1.59% |
|
9
XWELL
XWEL
$7.32M
| $7.32M | $0.7340 | 1.81% |
|
10
ENDRA Life Sciences
NDRA
$7.11M
| $7.11M | $4.74 | 7.06% |
|
11
Advanced Biomed Inc
ADVB
$6.58M
| $6.58M | $3.98 | 18.4% |
|
12
VolitionRx Ltd
VNRX
$5.41M
| $5.41M | $0.1801 | 4.46% |
|
13
iSpecimen
ISPC
$2.31M
| $2.31M | $0.9170 | 11% |
|
14
bioAffinity Technologies
BIAF
$2.24M
| $2.24M | $3.73 | 5.81% |
|
Micro Cap Diagnostics & Research Stocks at a Glance
Diagnostics and research companies run laboratory testing, imaging, and analytical services, and supply the instruments behind them. Testing volumes are recurring and largely non-discretionary, while research-tools demand follows pharma and academic R&D budgets.
There are 14 micro cap Diagnostics & Research stocks — companies in the Diagnostics & Research industry with a market cap under $250M — worth a combined $858M.
The largest by market cap are Biodesix (BDSX) at $250M, Exagen (XGN) at $187M and Burning Rock Biotech (BNR) at $136M.
Among institutional investors, bioAffinity Technologies (BIAF) drew the most net new fund positions in Q2 2026: 10 funds opened new positions, taking total fund holders up 7 (58%) quarter-over-quarter.
- Combined market cap: $858M across 14 stocks.
- Micro Cap: market cap under $250M.
- Largest constituent: Biodesix (BDSX), $250M market cap.
- Most net new fund positions in Q2 2026: bioAffinity Technologies (BIAF), +7 holders.
Market caps and prices updated daily; fund activity based on aggregated SEC 13F filings for Q2 2026.